^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
itanistomig (LB101)
i
Other names: LB101, PD-L1xCD47 LockBody, LB-101, LB 101
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Centessa
Drug class:
PD-L1 inhibitor, CD47 inhibitor
Related drugs:
2ms
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=25, Terminated, Centessa Pharmaceuticals (UK) Limited | Trial completion date: Jan 2027 --> Sep 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2025 --> Jan 2025; Sponsor terminated the study due to non-safety reasons. Based on the data and the current competitive landscape, Sponsor made the decision to close the study.
Trial completion date • Trial termination • Trial primary completion date • First-in-human
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
PD-L1 expression
|
itanistomig (LB101)
10ms
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants with Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=25, Active, not recruiting, Centessa Pharmaceuticals (UK) Limited | Recruiting --> Active, not recruiting | N=190 --> 25 | Trial primary completion date: Jan 2027 --> Oct 2025
Enrollment closed • Enrollment change • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
PD-L1 expression
|
itanistomig (LB101)
over2years
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=180, Recruiting, Centessa Pharmaceuticals (UK) Limited
New P1/2 trial • Metastases
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
PD-L1 expression
|
itanistomig (LB101)
Share via
